Zobrazeno 1 - 2
of 2
pro vyhledávání: '"[Lu]Lu-DOTATOC"'
Autor:
Henrik Bluhme, Anne Charlotte Bekker, Peter Iversen, Gerda Elisabeth Villadsen, Peter Frøhlich Staanum, Anne Kirstine Arveschoug
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-7 (2020)
Arveschoug, A K, Bekker, A C, Iversen, P, Bluhme, H, Villadsen, G E & Staanum, P F 2020, ' Extravasation of [ 177 Lu]Lu-DOTATOC : case report and discussion ', EJNMMI research, vol. 10, 68 . https://doi.org/10.1186/s13550-020-00658-6
Arveschoug, A K, Bekker, A C, Iversen, P, Bluhme, H, Villadsen, G E & Staanum, P F 2020, ' Extravasation of [ 177 Lu]Lu-DOTATOC : case report and discussion ', EJNMMI research, vol. 10, 68 . https://doi.org/10.1186/s13550-020-00658-6
Background In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid complications. The literature on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3107807124d8e5b91cc5f855472f60b
http://link.springer.com/article/10.1186/s13550-020-00658-6
http://link.springer.com/article/10.1186/s13550-020-00658-6
Autor:
Mirco Bartolomei, Eugenia Tonini, Petra Martini, Alessandra Boschi, Luca Lodi, Corrado Cittanti, Aldo Carnevale, Alberto Nieri, Licia Uccelli, Matteo Caracciolo, Luca Urso, Melchiore Giganti, Stefano Panareo
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 13, Iss 1463, p 1463 (2021)
Pharmaceutics, Vol 13, Iss 1463, p 1463 (2021)
The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee0a1e3fcb1ba9faf6641382f103d254
http://europepmc.org/articles/PMC8469896
http://europepmc.org/articles/PMC8469896